James Huffman, MD
Ophthalmology · London, KYNPI 1639166069
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,374 of the $6,238 with a category attached, or 70.1%. 21 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 33.0% of the total. Reporting peaked in 2019 at $2,325 and has fallen 75.6% since, to $568 in 2025.
Across 134 payments — averaging $46.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- Carl Zeiss Meditec USA, Inc.$980
- Alcon$783
- Sun Pharmaceutical Industries Inc.$576
- Bausch & Lomb Americas Inc.$435
- AbbVie$353
- plus $1K from 15 others
Across 6 payments — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$18K
What the payments were for
- Travel & lodging$1,86430%
- Food & beverage$4,37470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 14 | $2,061 |
| Carl Zeiss Meditec USA, Inc. | 8 | $980 |
| Alcon | 20 | $783 |
| Sun Pharmaceutical Industries Inc. | 19 | $576 |
| Bausch & Lomb Americas Inc. | 16 | $435 |
| AbbVie(2 entities) | 15 | $353 |
| Aerie Pharmaceuticals, Inc. | 12 | $255 |
| Glaukos Corporation | 1 | $136 |
| Biotissue Holdings Inc. | 3 | $116 |
| Novartis | 6 | $104 |
| Mallinckrodt Hospital Products Inc. | 4 | $86 |
| Rxsight Inc | 1 | $78 |
| Oyster Point Pharma, Inc. | 3 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $40 |
| Tarsus Pharmaceuticals, Inc. | 1 | $40 |
| Astellas Pharma US Inc | 2 | $36 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Ocular Therapeutix, Inc. | 2 | $32 |
| Alimera Sciences, Inc. | 1 | $18 |
| Beaver-visitec International, Inc. | 1 | $17 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,374
- Tecnis Multifocal Family of 1-piece IOLS$1,374
- Tecnis Symfony IOL$1,374
- QUATERA 700$787
- CEQUA$346
- Clareon$226
- Tecnis Simplicity$149
- Tecnis IOL$142
- CE-marked KXLA system$136
- Centurion$133
- AcrySof$128
- INFUSE$125
- TECNIS Presbyopia-Correcting IOLs$124
- Rhopressa$111
- Rocklatan$111
How this compares
$6,238 in reported general payments places this provider in the 85th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 95 | $116,111 |
| RestasisCyclosporine | 82 | $93,248 |
| Prednisolone Acetate | 1,401 | $61,152 |
| LumiganBimatoprost | 104 | $54,276 |
| MoxifloxacinMoxifloxacin Hcl | 1,149 | $30,870 |
| RocklatanNetarsudil Mesylat/Latanoprost | 64 | $24,969 |
| CombiganBrimonidine Tartrate/Timolol | 69 | $22,908 |
| Ketorolac Tromethamine | 1,115 | $22,718 |
| RhopressaNetarsudil Mesylate | 21 | $13,636 |
| Brimonidine Tartrate | 186 | $10,086 |
| CequaCyclosporine | 14 | $8,934 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 58 | $7,650 |
| Latanoprost | 754 | $6,805 |
| Cyclosporine | 11 | $5,392 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $5,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $353 | $174,363266 claims |
| Bausch & Lomb Americas Inc.Xiidra | $435 | $116,11195 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $255 | $38,60585 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $576 | $8,93414 claims |
| AlconSimbrinza | $783 | $5,01720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in London
- Mark HuffmanLondon$12K
- Rebekah HuffmanLondon$4K
- Edward HollandEdgewood$678K
- Gary WortzLexington$159K
- Jeremy ClarkLouisville$131K
- Bruce KofflerLexington$49K
- Guruprasad PattarLouisville$36K
- Jeffery TaylorPaducah$18K
- Asim PirachaLexington$17K
- Gary FoulksLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.